Clinical pharmacokinetics of tyrosine kinase inhibitors

Nielka P. van Erp(Radboud University Nijmegen), Henk‐Jan Guchelaar(Leiden University Medical Center), Hans Gelderblom(Leiden University Medical Center)
Cancer Treatment Reviews
September 6, 2009
10.1016/j.ctrv.2009.08.004
Cited by 498

Related Papers

Genetics of rheumatoid arthritis contributes to biology and drug discovery
|Nature|2013|2.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k